Cytotoxic

INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor growth, extends survival and increases…

London, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Cytotoxic Drugs and HPAPI Manufacturing Market (4th Edition), 2022 – 2035” report to its list of offerings. Manufacturing of highly potent compounds…

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with…

Precomplexing NK cells with Innate Cell Engagers (ICE® molecules) results in a CAR-like NK cell product, whose magnitude and specificity of antibody-dependent cellular cytotoxicity (ADCC) remain unaffected after one freeze-thaw cycle…